Delcath Systems Inc (DCTH)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Delcath Systems Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 1 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 13.00 $ — 91% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/04/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AAQS
6/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% 51.8%
- Exp. sales growth 3Y > 5% 23.8%
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% 23.8%
- Net debt < 4x EBIT -136.5x
- EBIT positive, 10Y straight 1
- Max. EBIT decline < 50% 0.0%
- Return on equity > 15% 2.4%
- ROCE > 15% 0.6%
- Expected return > 10% 29.6%
View all AAQS quality stocks · Read the methodology at AlleAktien
Source: fundamental data
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
8 of 10 Growth gemTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 215.2% passed
- More than 10% revenue growth is expected for the coming year 26.5% passed
- Share count grows by less than 3% a year 65.1% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 153.7% passed
- Gross margin at 40% or higher and without meaningful erosion 86.2% passed
- Goodwill from acquisitions does not grow faster than revenue 0.0% passed
- Net debt below twice EBITDA 90 m net cash passed
- Operating cash flow covers the profits of the last three years 44 m passed
- Return on capital at 15% or higher, or up versus two years ago 0.6% passed
- Insiders hold at least 10% or are net buyers 8.1% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Analysts & Price Target
The price target sits 65.8% above the current price.
- Consensus
- Strong Sell
- Analyst Ratings
- 6
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -0.61 | -0.91 – -0.44 | 103 | -856.3% | 4 |
| 12/31/2027 | -0.51 | -1.23 – -0.15 | 131 | 15.7% | 4 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.16 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.10 | – | 15 | 2,701.50 | -22.50 | -1 | -1 |
| 2025: Q1 | 0.03 | – | 20 | 530.30 | 5.40 | 2 | 2 |
| 2025: Q2 | 0.08 | – | 24 | 211.00 | 11.20 | 7 | 7 |
| 2025: Q3 | 0.02 | -55.50 | 21 | 83.60 | 4.00 | 5 | 4 |
| 2025: Q4 | -0.05 | – | 21 | 37.30 | -9.10 | 8 | 8 |
| 2026: Q1 | -0.03 | -200.10 | 25 | 26.30 | -4.30 | 1 | 0 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 2 | -16 | -18 | – | -14 | -1 | 35 |
| 2017 | 3 | -18 | -45 | – | -15 | 1 | 9 |
| 2018 | 3 | -27 | -19 | – | -15 | -15 | 7 |
| 2019 | 2 | -20 | -9 | -342.82 | -24 | -6 | 14 |
| 2020 | 2 | -21 | -24 | -8.34 | -23 | 22 | 35 |
| 2021 | 4 | -25 | -26 | -3.59 | -23 | 12 | 33 |
| 2022 | 3 | -34 | -37 | -4.12 | -25 | -6 | 18 |
| 2023 | 2 | -38 | -48 | -2.94 | -31 | 16 | 39 |
| 2024 | 37 | -12 | -26 | -0.93 | -19 | 69 | 77 |
| 2025 | 85 | 1 | 3 | 0.07 | 23 | 111 | 124 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Delcath Systems, Inc., ein interventionell-onkologisches Unternehmen, konzentriert sich auf die Behandlung von primären und metastasierten Leberkrebserkrankungen in den USA und Europa.
| Employees | 156 |
|---|---|
| Headquarters | Queensbury, NY |
| Address | 566 Queensbury Avenue, 12804 Queensbury, United States |
| Phone | 212 489 2100 |
| Website | delcath.com |
| IPO Date | 29. May 2018 |
| ISIN | US24661P8077 |
| Stock Split | 1:700 on 12/24/2019 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Gerard J. Michel MBA, MS | CEO & Director | 1963 |
| Martha S. Rook Ph.D. | Chief Operating Officer | 1971 |
| Vojislav Vukovic M.D., M.Sc., Ph.D. | Chief Medical Officer | 1967 |
| Sandra Pennell CPA | Chief Financial Officer | 1979 |
| David Hoffman J.D. | General Counsel, Corporate Secretary & Chief Compliance Officer | 1970 |
| Johnny John M.D. | Senior Vice President of Clinical Operations & Medical Affairs | 1965 |
| Kevin Muir | Chief Commercial Officer | – |
| Michael Brunner M.D. | Senior Vice President of Interventional Oncology | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.